



Analyse radiomique corps-entier d'images TEP/TDM en cancérologie: projet **NEMO-PET**



Projet NEMO-PET

= **N**ew prognostic **m**etastatic phen**o**types based on the analysis of whole-body **PET/CT** images using Artificial Intelligence.

Objectifs :

- ✓ Identifier et caractériser de **nouveaux phénotypes au stade métastatique**.
- ✓ Optimiser la **prise en charge thérapeutique** des patients.

Pourquoi ?

- ✓ **Unique stade IV** → patients métastatiques (American Joint Committee on Cancer).
- ✓ **Différents pronostics** → nombre et type d'organes affectés, degré d'invasion...



1. Contexte scientifique



Bon pronostic mais hétérogène, surtout pour les patientes métastatiques





Exploitation avancée des images corps-entier TEP/TDM au 18F-FDG



Déterminer si la combinaison des caractéristiques cliniques et radiomiques du corps entier, y compris les régions malignes et non tumorales, peut prédire la survie globale chez des patientes atteintes d'un cancer du sein métastatique.


2. Matériels & Méthodes: base de données

- ✓ Images TEP/TDM au 18F FDG pré-thérapeutique
- ✓ 4 sous-types moléculaires : **HR+ HER2-**, **HR+ HER2+**, **HER2+**, **TNBC**
- ✓ Suivi à 24 mois
- ✓ Séparation de la cohorte en deux groupes :
 - ✓ **Train** : patientes incluses entre **2008 et 2017**
 - ✓ **Test** : patientes incluses entre **2018 et 2019**
- ✓ Données cliniques : âge, IMC, statut HER2, expression des récepteurs hormonaux (HR)




Segmentations automatiques : régions non-tumorales

TotalSegmentator (<https://github.com/wasserth/TotalSegmentator>)



Modèle « tissu_types » (licence) :

- ✓ Graisse sous-cutanée (bleu)
- ✓ Graisse viscérale (rose)
- ✓ Muscle squelettique (jaune)




Modèle « total » :

- ✓ Rate (rouge)

Segmentations automatiques : tumeur primaire et métastases



LION (<https://github.com/LalithShiyam/>)




→ Seuillage à 4 SUV

Extraction des index radiomiques




LIFEx (www.lifexsoft.org)



CT



PET/CT



PET

Index radiomiques :

- Lésions → **TMTV** & **Dmax**
- Muscles → **SULmean**, **HUmean**, **Volume**
- Rate → **SULmean**
- Graisse sous-cutanée (Fat_SC) → **SULmean**, **HUmean**, **Volume**
- Graisse viscérale (Fat_V) → **SULmean**, **HUmean**, **Volume**



Analyses statistiques

- ✓ Variables en continu
- ✓ Modèles de Cox et sélection de variables avec step AIC : **clinical**, **clinical+radiomic**, **organomic**,
clinical+radiomic+organomic
- ✓ Prédiction d'un score de risque
- ✓ Stratification en deux et trois groupes :
 - Par la médiane et les quartiles (q1 et q3)
 - **Par les fonctions rhier et rlr (log rank)**
 - Par la courbe time ROC (index de Youden) → uniquement 2 groupes
 - Par la fonction survcutpoint (log rank) → uniquement 2 groupes
- ✓ Analyse de survie à 1 an et 2 ans : courbes de Kaplan Meier (OS)




Calcul de l'index de composition corporelle (BCi)

- ✓ Variables en continu
- ✓ Modèle de Cox et sélection de variables avec step AIC: **organomic (SULmean, Humean, Volumes de la graisse sous-cutanée, viscérale et des muscles)**
- ✓ Prédiction d'un score de risque

3. Résultats

TRAIN (n=370)




Number at risk

Strata	0	10	20	30	40	50
Subtype=HER2+	40	39	37	32	25	17
Subtype=HR+HER2+	57	57	56	48	41	32
Subtype=HR+HER2-	200	193	181	157	126	95
Subtype=TNBC	73	69	49	35	21	11

Time


TEST (n=120)



Number at risk

Strata	0	10	20	30	40	50
Subtype=HER2+	23	22	22	13	0	0
Subtype=HR+HER2+	7	7	7	2	0	0
Subtype=HR+HER2-	62	60	58	35	8	0
Subtype=TNBC	28	25	20	6	0	0

Time




Number at risk

Strata	0	10	20	30	40	50
Group=Test	120	114	107	56	8	0
Group=Train	370	358	323	272	213	155

Time

Caractéristiques patientes



	Train (n = 370)	Test (n = 120)	p (Wilcoxon test)
Age (year)	53 ± 13	52 ± 13	0.52
BMI (kg/m ²)	25.9 ± 5.2	25.8 ± 5.6	0.47
HER2			0.89
Positive	97 (26%)	30 (25%)	
Negative	273 (74%)	90 (75%)	
HR			0.02
Positive	257 (69%)	69 (58%)	
Negative	113 (31%)	51 (42%)	
Dmax (cm)	33 ± 22	34 ± 24	0.85
TMTV (mL)	110 ± 291	120 ± 252	0.57
SULmean Fat SC	0.27 ± 0.06	0.27 ± 0.05	0.38
SULmean Fat V	0.64 ± 0.16	0.65 ± 0.13	0.19
SULmean Skeletal muscles	0.52 ± 0.09	0.53 ± 0.08	0.11
SULmean Spleen	1.18 ± 0.25	1.22 ± 0.22	0.05
HUmean Fat SC	-91.6 ± 7.3	-91.3 ± 7.2	0.52
HUmean Fat V	-71.2 ± 13.8	-71.1 ± 12.1	0.72
HUmean Skeletal muscles	34.1 ± 7.9	33.6 ± 7.3	0.46
Volume Fat SC (mL)	21 297 ± 8629	22 329 ± 9394	0.37
Volume Fat V (mL)	2290 ± 1658	2888 ± 1446	0.85
Volume Skeletal muscles (mL)	13 624 ± 2300	14 172 ± 2559	0.04

mean ± sd
mean (%)

Quantitative data: Wilcoxon test



Qualitative data: chi² test

Index de composition corporelle (BCi*) : Train-Test


*BCi basé sur: Volume Fat SC & V, SULmean Muscles, HUmean Fat SC & Muscles

	min	q1	median	mean	q3	max
Train	0.40	0.76	0.94	1.09	1.24	4.90
Test	0.49	0.80	0.93	1.07	1.21	2.81

p = 0.85



Corrélation de Spearman



***BCi** basé sur: Volume Fat SC & V, SULmean Muscles, HUmean Fat SC & Muscles

BMI corrélé à :

- Volume Fat SC (rS = 0.91)
- Volume Fat V (rS = 0.72)

TMTV & **Dmax** : rS = 0.56

Index de composition corporelle (BCi) corrélé à :

- HUmean muscles (rS = 0.62)
- Age (rS = 0.59)
- Volume muscles (rS = 0.33)

HUmean muscles corrélé à :

- Volume Fat V (rS = 0.71)
- HUmean Fat V (rS = 0.71)
- Age (rS = 0.62)

BCi corrélé à :

- HUmean muscles (rS = 0.62)
- Age (rS = 0.59)

Analyses multivariées – TRAIN – Clinical – COX

ENTREE

- **HR**: POSITIVE vs **NEGATIVE**
- **HER2**: POSITIVE vs **NEGATIVE**
- **Age**
- **BMI**

SORTIE (STEP AIC)

```
coxph(formula = Surv(Time, Status) ~ HR + HER2 + Age, data = model_train)
```

n= 370, number of events= 157

	coef	exp(coef)	se(coef)	z	Pr(> z)	
HRPOS	-0.794557	0.451781	0.172552	-4.605	4.13e-06	***
HER2POS	-1.219588	0.295352	0.250809	-4.863	1.16e-06	***
Age	0.017532	1.017687	0.005998	2.923	0.00347	**

signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1

	exp(coef)	exp(-coef)	lower .95	upper .95
HRPOS	0.4518	2.2135	0.3221	0.6336
HER2POS	0.2954	3.3858	0.1807	0.4829
Age	1.0177	0.9826	1.0058	1.0297

Concordance= 0.688 (se = 0.021)
Likelihood ratio test= 53.82 on 3 df, p=1e-11
Wald test = 47.87 on 3 df, p=2e-10
Score (logrank) test = 49.68 on 3 df, p=9e-11



Poor OS:

 Low values

 High values



Analyses multivariées – TRAIN – Clinical – OS

→ Groupes déterminés avec les fonctions rhier et rlr (log rank), **ns = 45**



Analyses statistiques : analyses multivariées – TEST – Clinical – OS

→ Groupes déterminés avec les fonctions rhier et rlr (log rank)



Analyses multivariées – TRAIN – RADIOMIC – COX

ENTREE

- TMTV
 - DMAX

SORTIE (STEP AIC)

```
coxph(formula = Surv(Time, Status) ~ Dmax, data = model_train)

n= 370, number of events= 157

      coef exp(coef) se(coef)      z Pr(>|z|)
Dmax 0.006582  1.006604 0.003617  1.82  0.0688 .
---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1

      exp(coef) exp(-coef) lower .95 upper .95
Dmax      1.007      0.9934    0.9995    1.014

Concordance= 0.554  (se = 0.025 )
Likelihood ratio test= 3.26  on 1 df,   p=0.07
Wald test               = 3.31  on 1 df,   p=0.07
Score (logrank) test = 3.32  on 1 df,   p=0.07
```



Poor OS:

Low values

High values



Analyses multivariées – TRAIN – RADIOMIC – OS

→ Groupes déterminés avec les fonctions rhier et rlr (log rank), **ns = 45**



Analyses multivariées – TEST – RADIOMIC – OS

→ Groupes déterminés avec les fonctions rhier et rlr (log rank)



Analyses multivariées – TRAIN – CLIN+RADIOMIC – COX

ENTREE

- **HR:** POSITIVE vs **NEGATIVE**
- **HER2:** POSITIVE vs **NEGATIVE**
- **Age**
- **BMI**
- **TMTV**
- **Dmax**

SORTIE (STEP AIC)

```
coxph(formula = Surv(Time, Status) ~ HR + HER2 + Age + Dmax +  
      TMTV, data = model_train)
```

n= 370, number of events= 157

	coef	exp(coef)	se(coef)	z	Pr(> z)
HRPOS	-0.9992110	0.3681698	0.1894015	-5.276	1.32e-07 ***
HER2POS	-1.3587082	0.2569925	0.2580770	-5.265	1.40e-07 ***
Age	0.0177550	1.0179136	0.0060761	2.922	0.00348 **
Dmax	0.0115021	1.0115685	0.0041809	2.751	0.00594 **
TMTV	0.0004408	1.0004409	0.0002635	1.673	0.09429 .

Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1

	exp(coef)	exp(-coef)	lower .95	upper .95
HRPOS	0.3682	2.7161	0.2540	0.5337
HER2POS	0.2570	3.8912	0.1550	0.4262
Age	1.0179	0.9824	1.0059	1.0301
Dmax	1.0116	0.9886	1.0033	1.0199
TMTV	1.0004	0.9996	0.9999	1.0010

Concordance= 0.71 (se = 0.021)
Likelihood ratio test= 68.98 on 5 df, p=2e-13
Wald test = 60.61 on 5 df, p=9e-12
Score (logrank) test = 63.75 on 5 df, p=2e-12



Poor OS:

Low values

High values



Analyses multivariées – TRAIN – CLIN+RADIOMIC – OS

→ Groupes déterminés avec les fonctions rhier et rlr (log rank), **ns = 45**



Analyses multivariées – TEST – CLIN+RADIOMIC – OS

→ Groupes déterminés avec les fonctions rhier et rlr (log rank)



Analyses multivariées – TRAIN – BCI (Body Composition index) – COX

ENTREE

- V Fat SC
- V Fat V
- V Muscles
- SULmean Fat SC
- SULmean Fat V
- SULmean Muscles
- HUmean Fat SC
- HUmean Fat V
- HUmean Muscles

SORTIE

```
coxph(formula = Surv(Time, Status) ~ V_Fat_SC + V_Fat_V + SULmean_Muscles + HUmean_Fat_SC + HUmean_Muscles, data = model_train)
```

n= 370, number of events= 157

	coef	exp(coef)	se(coef)	z	Pr(> z)
V_Fat_SC	-2.314e-05	1.000e+00	1.559e-05	-1.484	0.1377
V_Fat_V	1.821e-04	1.000e+00	8.511e-05	2.140	0.0324 *
SULmean_Muscles	1.276e+00	3.584e+00	8.321e-01	1.534	0.1250
HUmean_Fat_SC	2.838e-02	1.029e+00	1.182e-02	2.402	0.0163 *
HUmean_Muscles	-2.669e-02	9.737e-01	1.392e-02	-1.917	0.0552 .

Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1

	exp(coef)	exp(-coef)	lower .95	upper .95
V_Fat_SC	1.0000	1.0000	0.9999	1.000
V_Fat_V	1.0002	0.9998	1.0000	1.000
SULmean_Muscles	3.5837	0.2790	0.7016	18.305
HUmean_Fat_SC	1.0288	0.9720	1.0052	1.053
HUmean_Muscles	0.9737	1.0270	0.9475	1.001

Concordance= 0.6 (se = 0.024)

Likelihood ratio test= 25.08 on 5 df, p=1e-04

Wald test = 27.48 on 5 df, p=5e-05

Score (logrank) test = 27.76 on 5 df, p=4e-05

Poor OS:

Low values

High values

Analyses multivariées – TRAIN – BCI (Body Composition index) – COX

ENTREE

- BCI
- SULmean Spleen

SORTIE

```
coxph(formula = Surv(Time, Status) ~ BCI, data = model_train)
```

```
n= 370, number of events= 157
```

	coef	exp(coef)	se(coef)	z	Pr(> z)
BCi	0.6187	1.8565	0.1067	5.799	6.67e-09 ***

signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1

	exp(coef)	exp(-coef)	lower .95	upper .95
BCi	1.856	0.5386	1.506	2.288

Concordance= 0.6 (se = 0.024)

Likelihood ratio test= 23.9 on 1 df, p=1e-06

Wald test = 33.63 on 1 df, p=7e-09

Score (logrank) test = 33.52 on 1 df, p=7e-09



Poor OS:

 Low values

 High values



Analyses multivariées – TRAIN – BCI (Body Composition index) – OS

→ Groupes déterminés avec les fonctions rhier et rlr (log rank), **ns = 45**



Analyses multivariées – TEST – BCI (Body Composition index) – OS

→ Groupes déterminés avec les fonctions rhier et rlr (log rank)



Analyses multivariées – TRAIN – CLIN+RADIOMIC+ORGANOMIC (BCI) – COX

ENTREE

- HR: POSITIVE vs **NEGATIVE**
- HER2: POSITIVE vs **NEGATIVE**
- Age
- BMI
- TMTV
- **Dmax**
- **Bci**
- SULmean Spleen

SORTIE

```
coxph(formula = Surv(Time, Status) ~ HR + HER2 + Dmax + Bci,  
      data = model_train)
```

n= 370, number of events= 157

	coef	exp(coef)	se(coef)	z	Pr(> z)
HRPOS	-1.099719	0.332965	0.192762	-5.705	1.16e-08 ***
HER2POS	-1.332100	0.263923	0.253511	-5.255	1.48e-07 ***
Dmax	0.012619	1.012699	0.003823	3.301	0.000964 ***
Bci	0.606227	1.833500	0.116231	5.216	1.83e-07 ***

signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1

	exp(coef)	exp(-coef)	lower .95	upper .95
HRPOS	0.3330	3.0033	0.2282	0.4858
HER2POS	0.2639	3.7890	0.1606	0.4338
Dmax	1.0127	0.9875	1.0051	1.0203
Bci	1.8335	0.5454	1.4600	2.3026

Concordance= 0.716 (se = 0.021)
Likelihood ratio test= 79.09 on 4 df, p=3e-16
Wald test = 74.32 on 4 df, p=3e-15
Score (logrank) test = 79.97 on 4 df, p=<2e-16



Poor OS:

 Low values

 High values



Analyses multivariées – TRAIN – CLIN+RADIOMIC+ORGANOMIC (BCI) – OS

→ Groupes déterminés avec les fonctions rhier et rlr (log rank), **ns = 45**




Analyses multivariées – TEST – CLIN+RADIOMIC+ORGANOMIC (BCI) – OS



→ Groupes déterminés avec les fonctions rhier et rlr (log rank)



Train




Test



(fonctions rhier et rlr)

Train



Survival	Low risk	Intermediate risk	High risk
1y - OS	100%	96%	92%
2y - OS	98%	90%	67%

Subtype	Low risk	Intermediate risk	High risk
TNBC (n=73)	0	0	73
HR+ HER2- (n=200)	0	142	58
HR+ HER2+ (n=57)	56	1	0
HER2+ (n=40)	1	39	0

- ➔ Toutes les TNBC sont **high risk**
- ➔ Les HR+HER2- sont partagées entre **intermediate** et **high risk**
- ➔ Quasi toutes les HR+ HER2+ sont **low risk**
- ➔ Quasi toutes les HER2+ sont **intermediate risk**

Test




Survival	Low risk	Intermediate risk	High risk
1y - OS	100%	97%	90%
2y - OS	100%	88%	78%

Subtype	Low risk	Intermediate risk	High risk
TNBC (n=28)	0	0	28
HR+ HER2- (n=62)	0	49	13
HR+ HER2+ (n=7)	6	1	0
HER2+ (n=23)	0	23	0

- ➔ Toutes les TNBC sont **high risk**
- ➔ Les HR+HER2- sont partagées entre **intermediate** et **high risk**
- ➔ Quasi toutes les HR+ HER2+ sont **low risk**
- ➔ Toutes les HER2+ sont **intermediate risk**

Train




Survival	Low risk	High risk	Δ
1y - OS	96%	86%	10%
2y - OS	87%	52%	35%

Subtype	Low risk	High risk
TNBC (n=73)	29	44
HR+ HER2- (n=200)	200	0
HR+ HER2+ (n=57)	57	0
HER2+ (n=40)	40	0

➔ Tous les high risk sont des TNBC

Test




Survival	Low risk	High risk	Δ
1y - OS	96%	87%	9%
2y - OS	88%	67%	21%




Subtype	Low risk	High risk
TNBC (n=28)	13	15
HR+ HER2- (n=62)	62	0
HR+ HER2+ (n=7)	7	0
HER2+ (n=23)	23	0

➔ Tous les high risk sont des TNBC

Train




Test



(fonctions rhier et rlr)

Train




Survival	Low risk	Intermediate risk	High risk
1y - OS	98%	94%	88%
2y - OS	96%	80%	52%

Subtype	Low risk	Intermediate risk	High risk
TNBC (n=73)	0	27	46
HR+ HER2- (n=200)	87	104	9
HR+ HER2+ (n=57)	57	0	0
HER2+ (n=40)	32	7	1

- ➔ Toutes le TNBC ne sont PAS **high risk** (≠clinical)
- ➔ On identifie une HER2+ **high risk** (≠clinical)
- ➔ Les HR+HER2- sont partagées entre dans les **3 groupes de risque** (≠clinical)
- ➔ Toutes les HER2+ ne sont pas **intermediate risk** (≠clinical)

Test




Survival	Low risk	Intermediate risk	High risk
1y - OS	98%	98%	84%
2y - OS	91%	83%	76%

Subtype	Low risk	Intermediate risk	High risk
TNBC (n=28)	0	10	18
HR+ HER2- (n=62)	28	27	7
HR+ HER2+ (n=7)	7	0	0
HER2+ (n=23)	20	3	0

- ➔ Toutes les TNBC ne sont PAS **high risk** (≠clinical)
- ➔ Les HR+HER2- sont partagées entre dans les **3 groupes de risque** (≠clinical)
- ➔ Toutes les HER2+ ne sont pas **intermediate risk** (≠clinical)

Train




Survival	Low risk	High risk	Δ
1y - OS	96%	86%	10%
2y - OS	88%	46%	42%

Subtype	Low risk	High risk
TNBC (n=73)	37	36
HR+ HER2- (n=200)	193	7
HR+ HER2+ (n=57)	57	0
HER2+ (n=40)	39	1

➔ Tous les high risk ne sont PAS des TNBC (≠clinical)

Test




Survival	Low risk	High risk	Δ
1y - OS	97%	77%	20%
2y - OS	88%	62%	26%



Subtype	Low risk	High risk
TNBC (n=28)	18	10
HR+ HER2- (n=62)	59	3
HR+ HER2+ (n=7)	7	0
HER2+ (n=23)	23	0

➔ Tous les high risk ne sont PAS des TNBC (≠clinical)

Train




Test



(fonctions rhier et rlr)

Train



Survival	Low risk	Intermediate risk	High risk
1y - OS	99%	96%	87%
2y - OS	97%	87%	54%

Subtype	Low risk	Intermediate risk	High risk
TNBC (n=73)	0	22	51
HR+ HER2- (n=200)	20	163	17
HR+ HER2+ (n=57)	57	0	0
HER2+ (n=40)	13	25	2

- ➔ Toutes le TNBC ne sont PAS **high risk** (≠clinical)
- ➔ On identifie deux HER2+ **high risk** (≠clinical)
- ➔ Les HR+HER2- sont partagées entre dans les **3 groupes de risque** (≠clinical)
- ➔ Toutes les HER2+ ne sont pas **intermediate risk** (≠clinical)

Test




Survival	Low risk	Intermediate risk	High risk
1y - OS	100%	97%	85%
2y - OS	95%	86%	74%

Subtype	Low risk	Intermediate risk	High risk
TNBC (n=28)	0	7	21
HR+ HER2- (n=62)	6	50	6
HR+ HER2+ (n=7)	7	0	0
HER2+ (n=23)	8	15	0

- ➔ Toutes les TNBC ne sont PAS **high risk** (≠clinical)
- ➔ Les HR+HER2- sont partagées entre dans les **3 groupes de risque** (≠clinical)
- ➔ Toutes les HER2+ ne sont pas **intermediate risk** (≠clinical)

Train




Survival	Low risk	High risk	Δ
1y - OS	94%	84%	10%
2y - OS	84%	50%	34%

Subtype	Low risk	High risk
TNBC (n=73)	41	32
HR+ HER2- (n=200)	188	12
HR+ HER2+ (n=57)	57	0
HER2+ (n=40)	40	0

- ➔ Toutes les high risk ne sont PAS que des TNBC (≠clinical)
- ➔ Toutes les patients HER2+ sont low risk (≠clin+radiomic)

Test



Survival	Low risk	High risk	Δ
1y - OS	98%	71%	27%
2y - OS	89%	57%	32%

Subtype	Low risk	High risk
TNBC (n=28)	16	12
HR+ HER2- (n=62)	60	2
HR+ HER2+ (n=7)	7	0
HER2+ (n=23)	23	0




-> Toutes les high risk ne sont PAS que des TNBC (≠clinical)

TEST (n=120)

CLINICAL

CLINICAL+RADIOMIC

CLINICAL+RADIOMIC+BCI



Survival	Low risk	High risk	Δ
1y - OS	96%	87%	9%
2y - OS	88%	67%	21%

Survival	Low risk	High risk	Δ
1y - OS	97%	77%	20%
2y - OS	88%	62%	26%

Survival	Low risk	High risk	Δ
1y - OS	98%	71%	27%
2y - OS	89%	57%	32%

Subtype	Low risk	High risk
TNBC (n=28)	13	15
HR+ HER2- (n=62)	62	0
HR+ HER2+ (n=7)	7	0
HER2+ (n=23)	23	0

Subtype	Low risk	High risk
TNBC (n=28)	18	10
HR+ HER2- (n=62)	59	3
HR+ HER2+ (n=7)	7	0
HER2+ (n=23)	23	0



Subtype	Low risk	High risk
TNBC (n=28)	16	12
HR+ HER2- (n=62)	60	2
HR+ HER2+ (n=7)	7	0
HER2+ (n=23)	23	0

TEST_TNBC (n=28)

CLINICAL

CLINICAL+RADIOMIC

CLINICAL+RADIOMIC+BCi



Survival	Low risk	High risk	Δ
1y - OS	92%	87%	5%
2y - OS	77%	67%	10%


Survival	Low risk	High risk	Δ
1y - OS	94%	80%	14%
2y - OS	78%	60%	18%

Survival	Low risk	High risk	Δ
1y - OS	100%	75%	25%
2y - OS	81%	58%	23%




4. Conclusions

- ✓ Le modèle clinique est capable d'identifier plusieurs groupes de risque à partir de l'âge, le statut HER2 et l'expression des récepteurs hormonaux.

Train




Test



4. Conclusions


- ✓ L'ajout des informations **radiomiques** et **organomiques** a permis d'obtenir une meilleure stratification des patientes TNBC en identifiant des patientes de bons et mauvais pronostics.

CLINICAL




Subtype	Low risk	High risk
TNBC (n=28)	13	15
HR+ HER2- (n=62)	62	0
HR+ HER2+ (n=7)	7	0
HER2+ (n=23)	23	0

CLINICAL+RADIOMIC



Subtype	Low risk	High risk
TNBC (n=28)	18	10
HR+ HER2- (n=62)	59	3
HR+ HER2+ (n=7)	7	0
HER2+ (n=23)	23	0

CLINICAL+RADIOMIC+BCI



Subtype	Low risk	High risk
TNBC (n=28)	16	12
HR+ HER2- (n=62)	60	2
HR+ HER2+ (n=7)	7	0
HER2+ (n=23)	23	0

5. Perspectives



- ✓ Ajouter des nouvelles patientes dans la base **Test**
- ✓ Essayer de s'affranchir de l'effet « sous-type » en :
 - Créant un modèle **sans les variables histologiques** HR et HER2
 - Créant un modèle **TMTV & Dmax** pour chaque sous-type afin d'identifier et regrouper les patientes **mauvais/bon** pronostic quelque soit le sous-type
- ✓ Développer un modèle de classification pronostique à 24 mois
- ✓ Développer un modèle capable de stratifier les patientes HR+_HER2- en 3 groupes de risque en fonction de l'OS
- ✓ ...